半乳糖凝集素-3在慢性肾脏病中的研究进展

Research progress of galectin-3 in chronic kidney disease

慢性肾脏病(chronic kidney disease,CKD)是一个日益严重的健康问题,其特征是肾功能的进行性和不可逆性丧失。随着肾功能下降,CKD患者最终会出现严重的电解质代谢紊乱、全身各系统疾病,甚至危及生命。近年来,半乳糖凝集素-3(galectin-3,Gal-3)作为一种β-半乳糖苷结合蛋白备备受关注。研究发现Gal-3参与调节免疫系统、炎症反应和组织纤维化等病理生理过程,其在糖尿病肾病、高血压肾病和慢性肾小球肾炎等CKD中的研究价值尤为突出,甚至有学者认为Gal-3可能成为判断CKD预后的生物学标志物以及潜在的新治疗靶点。

Chronic kidney disease(CKD)is an increasingly serious health problem,which is characterized by progressive and irreversible loss of renal function.With the decline of renal function,CKD patients will eventually develop into serious electrolyte metabolism disorder,systemic diseases,which can be life-threatening.In recent years,as a chimeric type ofβ-galactoside binding protein,galectin-3(Gal-3)has attracted much attention.It has been found that Gal-3 is involved in the regulation of immune system,inflammatory response,tissue fibrosis and other physiological and pathological processes,and Gal-3 becomes particularly valuable in the study of CKD,such as diabetic nephropathy,hypertensive nephropathy and chronic glomerulonephritis.Even some scholars think that Gal-3 may become a biological marker for judging the prognosis of CKD and a potential new therapeutic target.